Table 1.
Analysis of clinical indexes between the dapagliflozin and control groups in patients with type 2 diabetes mellitus (means ± SD, n = 20)
|
Parameter
|
Dapagliflozin
|
Control
|
Wilcoxon W
|
P
value
|
| Age | 39.80 ± 5.136 | 39.75 ± 5.990 | 397.000 | 0.724 |
| Smoking history | 16.55 ± 9.720 | 10.25 ±11.639 | 353.000 | 0.111 |
| Height (m) | 1.7670 ± 0.07255 | 1.7505 ± 0.090 | 389.000 | 0.569 |
| Weight (kg) | 74.950 ± 8.9176 | 72.525 ± 6.6718 | 381.500 | 0.440 |
| BMI (kg/m2) | 24.3695 ± 1.82674 | 24.014 ± 1.6715 | 385.00 | 0.499 |
| Waist circumference (cm) | 96.350 ± 2.3402 | 93.525 ± 5.7502 | 325.000 | 0.021 |
| Hip circumference (cm) | 96.975 ± 2.4413 | 99.225 ± 6.4062 | 398.500 | 0.755 |
| Waist-hip ratio | 0.9937 ± 0.0132391 | 0.9494 ± 0.04815 | 308.000 | 0.006 |
| SBP (mmHg) | 124.80 ± 5.297 | 120.40 ± 5.423 | 323.500 | 0.018 |
| DBP (mmHg) | 78.85 ± 5.724 | 77.95 ± 5.969 | 394.500 | 0.671 |
| Diabetes course (yr) | 2.575 ± 1.2169 | 2.825 ± 1.8229 | 396.500 | 0.713 |
| TG | 1.884 ± 1.2172 | 0.979 ± 0.2376 | 1.2172203 | 0.002 |
| LDL | 2.8585 ± 1.0440 | 1.5975 ± 0.5079 | 1.0439867 | < 0.001 |
| HDL | 1.0855 ± 0.2457 | 1.023 ± 0.1246 | 0.2457100 | 0.560 |
| APOA1 | 1.3630 ± 0.2022 | 1.2625 ± 0.1882 | 0.2022271 | 0.010 |
| APOB100 | 0.9425 ± 0.2651 | 1.0345 ± 0.1521 | 0.2651092 | 0.424 |
| CRP | 1.311 ± 0.9305 | 1.1635 ± 0.5462 | 0.9305511 | 0.967 |
| HbA1c | 6.7500 ± 0.6863 | 6.3700 ± 0.3827 | 0.6863327 | 0.032 |
| THCY | 12.030 ± 2.1451 | 12.4215 ± 1.2702 | 2.1450899 | 0.213 |
| RBP4 | 37.150 ± 5.6033 | 35.800 ± 4.3842 | 5.6033 | 0.446 |
| NEFA | 0.8245 ± 0.5849 | 1.026 ± 0.1099 | 0.5849019 | < 0.001 |
| FCP | 2.2770 ± 0.7903 | 2.231 ± 0.4151 | 0.7903104 | 0.525 |
| TC | 4.1950 ± 0.8378 | 3.7875 ± 0.4683 | 344.500 | 0.076 |
| IR | 2.7120 ± 1.7245 | 2.8440 ± .8424 | 358.500 | 0.163 |
| FINS | 8.4905 ± 4.4824 | 10.313 ± 3.2099 | 328.500 | 0.027 |
| FBP | 6.80 ± 1.105 | 6.15 ± 0.671 | 335.500 | 0.034 |
| Non-HDL | 3.05 ± 0.826 | 2.80 ± 0.410 | 364.000 | 0.142 |
| HOMA2- insulin | 75.6150 ± 20.339 | 89.460 ± 18.246 | 324.000 | 0.020 |
| HOMA2-S% | 61.6750 ± 21.1603 | 60.440 ± 14.789 | 400.000 | 0.787 |
| HOMA2-IR | 1.8185 ± 0.7285 | 1.7210 ± 0.3760 | 399.000 | 0.766 |
BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglycerides; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; APOA1: Apolipoprotein A1; ApoB100: Apolipoprotein B100; CRP: C-reactive protein; FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c; THCY: Homocysteine; RBP4: Retinol binding protein 4; NEFA: Non-esterified fatty acids; FCP: Fasting C-peptide; TC: Total cholesterol; FINS: Fasting plasma insulin level; HOMA2-B: Homeostatic model assessment-beta cell; HOMA2-S%: Homeostatic model assessment-insulin sensitivity; HOMA2-IR: Homeostatic model assessment-insulin resistance.